Search results
Results From The WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
On 28 December 2012, the U.S. Food and Drug Administration (FDA) approved bedaquiline (marketed as Sirturo by Johnson & Johnson) to treat multidrug-resistant tuberculosis, the first new treatment in 40 years. Sirturo is to be used in a combination therapy for patients who have failed standard treatment and have no other options.
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
However, most infections with M. tuberculosis do not cause disease, [169] and 90–95% of infections remain asymptomatic. [87] In 2012, an estimated 8.6 million chronic cases were active. [170] In 2010, 8.8 million new cases of tuberculosis were diagnosed, and 1.20–1.45 million deaths occurred (most of these occurring in developing countries).
For premium support please call: 800-290-4726 more ways to reach us
TB Alliance was conceived at a February 2000 meeting in Cape Town, South Africa, where 120 representatives from academia, industry, major government agencies, non-governmental organizations and donors gathered to discuss the problems of tuberculosis treatment. Participants stressed the need for faster-acting, novel TB drugs and highlighted the ...
Treatment for tuberculosis generally consists of antibiotics taken daily or weekly for a period of months. People with infectious tuberculosis must be isolated during that time, until they’re no ...
Extensively drug resistant tuberculosis is tuberculosis that is resistant to isoniazid and rifampicin, any fluoroquinolone, and any of the three second line injectable TB drugs (amikacin, capreomycin, and kanamycin). [1] TDR-TB has been identified in three countries; India, Iran, and Italy. The term was first presented in 2006, in which it ...